CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 379 enrolled
Drug / intervention
CyberKnife Stereotactic Radiosurgeryradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00643994
NCT00643994N/ACompleted
CompareCT.gov

Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution

Accuray Incorporated·interventional·Posted Mar 26, 2008·Updated May 9, 2023

In Brief

A clinical study evaluating CyberKnife Stereotactic Radiosurgery for Prostate Cancer and 4 related conditions. Completed, enrolled 379 participants across 23 sites.

Detailed Summary

The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms, Cancer of the Prostate
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2008
Enrollment StartDec 1, 2007
Primary CompletionJan 27, 2021
TodayJul 2, 2026
Enrollment to primary: 13.2 yearsPosted 18.3 years ago

Interventions

CyberKnife Stereotactic Radiosurgeryradiation

36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction